Promising Medical Stocks To Research - May 7th

Key Points

• Zoetis, Eli Lilly, Insmed, UnitedHealth, and Pfizer are MarketBeat's five medical stocks to watch, selected because they had the highest dollar trading volume among medical-sector names in recent days.
• These companies span animal health (Zoetis), diabetes and obesity drugs (Eli Lilly), rare-disease biopharma with ARIKAYCE (Insmed), diversified health services and insurance with Optum (UnitedHealth), and big‑pharma vaccines/COVID treatments (Pfizer). Investors are drawn to healthcare's growth drivers—drug development, aging populations, new technologies—but must weigh sector risks like regulatory approvals, clinical trial outcomes, patent expirations, and reimbursement pressure.

Zoetis, Eli Lilly and Company, Insmed, UnitedHealth Group, and Pfizer are the five Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of publicly traded companies whose primary business involves healthcare and medicine — including pharmaceuticals, biotechnology, medical device and diagnostics makers, hospitals and clinics, and health insurers and service providers. Investors buy them for exposure to the healthcare sector’s growth drivers (drug development, aging populations, new technologies) but must account for sector-specific risks like regulatory approvals, clinical trial outcomes, patent expirations and reimbursement pressures. These companies had the highest dollar trading volume of any Medical stocks within the last several days.

Zoetis (ZTS)

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Read Our Latest Research Report on ZTS

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Read Our Latest Research Report on LLY

Insmed (INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Read Our Latest Research Report on INSM

UnitedHealth Group (UNH)

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

Read Our Latest Research Report on UNH

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read Our Latest Research Report on PFE

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.